Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $3.6 million.

  • TransMedics' Cash from Financing Activities fell 5368.86% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year decrease of 3391.12%. This contributed to the annual value of $22.9 million for FY2024, which is 9428.75% down from last year.
  • According to the latest figures from Q3 2025, TransMedics' Cash from Financing Activities is $3.6 million, which was down 5368.86% from $7.1 million recorded in Q2 2025.
  • TransMedics' 5-year Cash from Financing Activities high stood at $394.0 million for Q2 2023, and its period low was $45000.0 during Q4 2021.
  • For the 5-year period, TransMedics' Cash from Financing Activities averaged around $31.9 million, with its median value being $3.0 million (2025).
  • Per our database at Business Quant, TransMedics' Cash from Financing Activities plummeted by 9971.8% in 2021 and then skyrocketed by 16615021.1% in 2023.
  • Over the past 5 years, TransMedics' Cash from Financing Activities (Quarter) stood at $45000.0 in 2021, then surged by 6711.11% to $3.1 million in 2022, then tumbled by 69.85% to $924000.0 in 2023, then grew by 28.35% to $1.2 million in 2024, then surged by 207.0% to $3.6 million in 2025.
  • Its Cash from Financing Activities was $3.6 million in Q3 2025, compared to $7.1 million in Q2 2025 and $3.0 million in Q1 2025.